Imperial College London
Alternate

Professor Mark Isalan - Deputy Head of Department

Faculty of Natural Sciences, Department of Life Sciences

Professor of Synthetic Biology
 
 
 
//

Contact

 

+44 (0)20 7594 6482m.isalan

 
 
//

Location

 

509Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Baddeley:2021:10.3389/fgeed.2021.745559,
author = {Baddeley, H and Isalan, M},
doi = {10.3389/fgeed.2021.745559},
journal = {Frontiers in Genome Editing},
title = {The application of CRISPR/Cas systems for antiviral therapy},
url = {http://dx.doi.org/10.3389/fgeed.2021.745559},
volume = {3},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - As CRISPR/Cas systems have been refined over time, there has been an effort to apply them to real world problems, such as developing sequence-targeted antiviral therapies. Viruses pose a major threat to humans and new tools are urgently needed to combat these rapidly mutating pathogens. Importantly, a variety of CRISPR systems have the potential to directly cleave DNA and RNA viral genomes, in a targeted and easily-adaptable manner, thus preventing or treating infections. This perspective article highlights recent studies using different Cas effectors against various RNA viruses causing acute infections in humans; a latent virus (HIV-1); a chronic virus (hepatitis B); and viruses infecting livestock and animal species of industrial importance. The outlook and remaining challenges are discussed, particularly in the context of tacking newly emerging viruses, such as SARS-CoV-2.
AU  - Baddeley,H
AU  - Isalan,M
DO  - 10.3389/fgeed.2021.745559
PY  - 2021///
SN  - 2673-3439
TI  - The application of CRISPR/Cas systems for antiviral therapy
T2  - Frontiers in Genome Editing
UR  - http://dx.doi.org/10.3389/fgeed.2021.745559
UR  - http://hdl.handle.net/10044/1/92483
VL  - 3
ER  -
Download